263
Participants
Start Date
September 30, 2008
Primary Completion Date
September 30, 2010
Study Completion Date
September 30, 2010
Placebo
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Droxidopa
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
North Shore Hospital, Manshasette
HAN Neurological Associates, Upland
Pennsylvania Hospital of the University of PA Health System- Department of Neurology, Philadelphia
Cncs, Ninds,Nih, Bethesda
Suncoast Neuroscience Associates, Inc, St. Petersburg
Bradenton Neurology, Inc, Bradenton
North Alabama Neuroscience, Huntsville
Nerological Reserch Center at Hattiesburg, Hattiesburg
University of Kansas Medical Center, Kansas City
Arkansas Cardiology, Little Rock
Baylor College of Medicine, Houston
Mayo Clinic-Arizona, Scottsdale
University of California, Irvine, Irvine
Evergreen Hospital Medical Center; Booth Gardner Parkinson's Care Center, Kirkland
University of Calgary, Calgary
University of Alberta, Edmonton
Movment Disorder Clinic Deer lodge Centre, Winnipeg
David B. King, - Private Clinic, Halifax
London Health Sciences Centre, UH, London
UHNresearch, Toronto
IRCM, Montreal
Lead Sponsor
Collaborators (1)
Chiltern International Inc.
INDUSTRY
Chelsea Therapeutics
INDUSTRY